Acceptability of a new 4-in-1 Abacavir/ Lamivudine/ Lopinavir/ Ritonavir paediatric fixed-dose combination: The caregiver–child dyads’ perspective
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir
Leave no one behind: Response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind